Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany.

Authors
Type
Published Article
Journal
Health economics review
Publication Date
Volume
4
Issue
1
Pages
32–32
Identifiers
DOI: 10.1186/s13561-014-0032-4
PMID: 26208932
Source
Medline
License
Unknown

Abstract

In this study, there were no significant differences in persistence among adalimumab, etanercept and infliximab treated patients. Consistent with previous research, there was a higher dose escalation for infliximab than for the two subcutaneous treatments, adalimumab or etanercept.

Statistics

Seen <100 times